Close Menu

NEW YORK – Molecular food safety testing company Clear Labs has developed an automated nanopore sequencing-based diagnostic COVID-19 assay platform that it plans to launch in the coming weeks.

On Thursday, the company announced an $18 million strategic funding round, part of which will go toward the commercialization of the COVID-19 platform. The round was led by Redmile Group, with participation from existing investors Wing VC, Menlo Ventures, Tyson Ventures, Khosla Ventures, GV, Felicis Ventures, and HBM Genomics, and brings the firm's total funding raised so far to $62 million.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.